ArticleNature communications2026
Robust footprinting with sample-specific Tn5 bias correction for bulk and single cell ATAC-seq.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Accurate detection of transcription factor (TF) and nucleosome occupancy from assay for transposase-accessible chromatin via sequencing (ATAC-seq) remains challenging due to sequence-dependent Tn5 cleavage bias. We show that this cleavage bias varies across samples and introduce TraceBind, an ATAC-seq footprinting framework that performs sample-specific Tn5 bias correction by fine-tuning a pretrained cleavage model using mitochondrial DNA reads, followed by multiscale detection with empirical false discovery rate control. Across bulk and single-cell ATAC-seq datasets, with validation by naked DNA controls, matched ChIP-seq and CUT&RUN experiments, and TF degradation perturbations, TraceBind reduces false positives while maintaining high sensitivity compared to existing methods. TraceBind enables improved downstream single-cell analyses, including transcription factor activity inference and cell age prediction. Base-resolution comparisons with DNA foundation model-based sequence annotations show enriched overlap but reveals many high-confidence footprints not captured by DNA foundation models, highlighting complementary regulatory information beyond what can be learned from DNA sequence alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.